Aridis Provides Corporate Update
24 juin 2024 17h58 HE
|
Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent...
New Approaches to Treating Infections in Cystic Fibrosis Patients - AR 501 Phase 2 Trial Update
17 janv. 2023 16h30 HE
|
Aridis Pharmaceuticals, Inc.
AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in CF patients Los Gatos, Calif., Jan. 17, 2023 ...